ArticleCancer research2018
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 49 citations in OpenAlex.
- Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.Nature communications · 2026Article
- Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An In Vivo MR Spectroscopy Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Tumor Microenvironment-Responsive Nanomedicine: Monitoring and Modulating the Tumor Microenvironment for Precision Cancer Therapy.International journal of nanomedicine · 2026Review
- Autophagy Upregulation in Mutant Isocitrate Dehydrogenase 1 (IDH1) Glioma Uncovers a Novel Therapeutic Target.Research square · 2025Article
- Artificial Intelligent-Enhanced Metabolite Profiling for Intraoperative IDH1 Genotyping in Glioma Using an Orthogonally Responsive SERS Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Isocitrate Dehydrogenase-Wildtype Glioma Adapts Toward Mutant Phenotypes and Enhanced Therapy Sensitivity Under D-2-Hydroxyglutarate Exposure.Biomedicines · 2025Article
- The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.Neuro-oncology · 2025Review
- Review
- IDH mutant high-grade gliomas.Frontiers in molecular neuroscience · 2025Review
- IDH inhibition in gliomas: from preclinical models to clinical trials.Nature reviews. Neurology · 2024Review
- Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.Nature communications · 2024Article
- Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells.Neuro-oncology · 2023Article
- Review
- Association between altered metabolism and genetic mutations in human glioma.Cancer reports (Hoboken, N.J.) · 2023Article
- The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma.PloS one · 2022Article
- Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Cell reports. Medicine · 2021Review
- The implications of IDH mutations for cancer development and therapy.Nature reviews. Clinical oncology · 2021Review
- Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.Neoplasia (New York, N.Y.) · 2021Article
- Lesion covariance networks reveal proposed origins and pathways of diffuse gliomas.Brain communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 1 institution in 1 country.
Matthew S WaitkusDepartment of Pathology, Duke University, Durham, North Carolina.
Christopher J PirozziDepartment of Pathology, Duke University, Durham, North Carolina.
Casey J MoureDepartment of Pathology, Duke University, Durham, North Carolina.
Bill H DiplasDepartment of Pathology, Duke University, Durham, North Carolina.
Landon J HansenDepartment of Pathology, Duke University, Durham, North Carolina.
Austin B CarpenterDepartment of Pathology, Duke University, Durham, North Carolina.
Rui YangDepartment of Pathology, Duke University, Durham, North Carolina.
Zhaohui WangDepartment of Pathology, Duke University, Durham, North Carolina.
Brian O IngramMetabolon Inc., Research Triangle Park, North Carolina.
Edward D KarolyMetabolon Inc., Research Triangle Park, North Carolina.
Robert P MohneyMetabolon Inc., Research Triangle Park, North Carolina.
Ivan SpasojevicDepartment of Medicine - Oncology, Duke University School of Medicine, Durham, North Carolina.
Roger E McLendonDepartment of Pathology, Duke University, Durham, North Carolina.
Henry S FriedmanPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Yiping HeDepartment of Pathology, Duke University, Durham, North Carolina.
Darell D BignerPreston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina.
Hai YanDepartment of Pathology, Duke University, Durham, North Carolina. hai.yan@duke.edu.
Duke University · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MTraining Program in Developmental & Stem Cell BiologyT32HD040372 · NICHD · DUKE UNIVERSITY · PI Terry H Lechler · 2001 to 2026
$8.9MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MRESEARCH TRAINING IN NEURO-ONCOLOGYT32CA074736 · NCI · DUKE UNIVERSITY · PI FRIEDMAN, HENRY S. · 1998 to 2014
$3.8MThe Role of IDH1 Mutations in Gliomagenesis and MetabolismR01CA140316 · NCI · DUKE UNIVERSITY · PI YAN, HAI · 2010 to 2019
$3.2MExploiting MTAP deletion for GBM therapeuticsR01NS101074 · NINDS · DUKE UNIVERSITY · PI HE, YIPING · 2017 to 2021
$1.7MRole of GLUD2 as a metabolic driver of gliomas with IDH1 mutationsR01NS096407 · NINDS · DUKE UNIVERSITY · PI ASHLEY, DAVID M. · 2016 to 2019
$1.4MNCI NIH HHS R01 CA140316NCI NIH HHS T32 CA074736NICHD NIH HHS T32 HD040372NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449NINDS NIH HHS R01 NS096407NINDS NIH HHS R01 NS101074
Abstract
Hotspot mutations in the isocitrate dehydrogenase 1 (
Indexed as
AnimalsBrain NeoplasmsEvolution, MolecularGene Expression Regulation, NeoplasticGene Knock-In TechniquesGliomaGlutamate DehydrogenaseHumansIsocitrate DehydrogenaseMaleMice, Inbred NODMice, Inbred StrainsMutagenesis, Site-DirectedProsencephalonProtein DomainsTransgenesGlutamate DehydrogenaseIDH1 protein, humanIdh1 protein, mouseIsocitrate Dehydrogenaseisocitrate dehydrogenase 2, mouse
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.